Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sequins As Novel Internal Controls to Improve Genomic Analysis

By LabMedica International staff writers
Posted on 16 Aug 2016
Researchers have developed an intuitive technology called “Sequins” – synthetic “mirror” DNA sequences that reflect the human genome and can be used to better map, navigate, and analyze complexity within the genome. More...
Currently human genome Sequins are freely available for research.

Scientists at the Garvan Institute of Medical Research (Darlinghurst, Sydney, NSW, Australia) developed the new technology. “Human genome sequencing is transforming biomedical research and healthcare,” said Dr. Tim Mercer, who led the development of Sequins, “And as genome sequencing is being increasingly used to diagnose disease, it is more important than ever that researchers and clinicians understand the accuracy of the genomic data they are looking at.”

Dr. Mercer and his team came up with the idea of adding Sequins, small stretches of synthetic DNA, to a patient’s DNA sample during sequencing. These Sequins (or sequencing spike-ins) then act as internal standards, helping researchers analyze the large data files generated during genome sequencing. The technology is based on an intuitively simple concept: the notion of mirror image DNA. “Sequins are, essentially, mirror images of natural DNA sequences. Like us, the genome has a ‘handedness’, and just as our right hand differs from our left hand, sequins differ from natural genome sequences. So sequins behave just like natural genome sequences, but they can be easily recognized as synthetic,” said Dr. Mercer.

When added to a sequencing reaction, sequins provide internal controls with which to assess the sensitivity and accuracy of genome sequencing. “A whole series of steps, first in the lab and then on the computer, are required to sequence a person’s genome or the genes that are expressed in different cells. Sequins are with the person’s DNA every step of the way: responding just as real DNA does at each step, yet unmistakably different from that real DNA. This allows a scientist to assess, and optimize, these different steps.”

Because sequins are added to each individual sample, they can provide a sample-by-sample assessment – something that has not previously been possible. “Sequins are the first technology to allow diagnostic statistics to be applied to each individual genome sequencing test,” said Dr. Mercer, “and we anticipate that their use will improve the reliability and sensitivity of genetic disease diagnosis.”

Cancer diagnosis is one area in which using Sequins should lead to improvements. “Incorporating Sequins into clinical tests for cancer diagnosis will increase the reliability of an individual diagnostic readout, reducing incorrect diagnoses and giving clinicians greater confidence in deciding the best course of treatment for their patient,” said Dr. Mercer.

Using Sequins will also make it possible to directly compare genomic data from research institutes and sequencing centers worldwide. “Sequins bring DNA sequencing to clinical standard, and will be an essential platform for genomic research and medicine,” said co-author Prof. John Mattick, Garvan’s executive director, “This is another important step in advancing Garvan’s mission to bring genomics to the clinic.”

The potential applications of Sequins are many. Because all genomes, from bacteria to human, have handedness, sequins can be similarly designed for any organism, or for almost any next-generation sequencing (NGS) application.

The Sequins technology is described in two linked studies, by Hardwick SA et al and by Deveson IW et al, both published August 8, 2016, in the journal Nature Methods.

Related Links:
Garvan Institute of Medical Research



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.